Thiabendazole, was first discovered to be an unusually potent broad spectrum anthelmintic (1, 2, 3, 4, 5) . Extensive acute and chronic toxicity studies in a variety of animal species have shown thiabendazole to be well tolerated even when administered orally over a 2-year period (6). More recently thiabendazole was discovered to suppress the growth of saprophytic fungi (7). The present paper deals with the effect of thiabendazole in vitro on various pathogenic and saprophytic fungi. Included in the latter group of organisms are cultures which are known to produce mycotoxins. Comparative studies were made with nystatin and griseofulvin.
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MATERIALS AND METHODS
Thiabendazole is a white, crystalline compound which has the following structural formula: cçt
The compound is only slightly soluble in water; its solubility is a function of pH, being more soluble in dilute acids and alkali than at neutral pH. Its maximum solubility with hydrochloric acid is at pH 2.5 where it will give a 1.5 per cent solution. It is a stable compound both as a solid and in solution and will form colored complexes with metals such as iron. Stock solutions of thiabendazole hydrochloride were prepared in sterile water whereas the relatively insoluble agents nystatin (Mycostatin sterile powder) and griseofulvin were homogenized to fine suspensions in 1 per cent Emulphor EL 720. The stock solutions or suspensions were freshly prepared at concentrations tenfold those employed in the test medium. In the present investigation the concentrations of nystatin are expressed as "Mycostatin." One mg of the powder was equivalent to approximately 3000 units.
The fungistatic activity of thiabendazole against the saprophytic fungi was determined by the streak method on agar plates. Drug concentrations ranging from 0.1 to 100 g per nil in Sabeuraud's Dextrose Agar (Difco) were employed. Penicillin and streptomycin at concentrations of 20 and 40 g per nil respectively, were added to the medium to control possible bacterial contamination. Control plates, with and without emulphor, were also run to evaluate the effect of the vehicle on fungal growth. The inocula were prepared by growing the cultures in Sabouraud's Dextrose liquid medium at 24° C and a fine suspension prepared by hand grinding the cultures in sterile glass homogenizers. The resulting fungal suspensions were streaked on the surface of the agar with a standard wire loop. The plates were incubated at 34° C and inspected daily for evidence of growth.
The terminal readings for the majority of the cultures were made after 4 days incubation. The lowest level of drug which prevented growth was recorded as the minimal inhibitory concentration.
The comparative fungistatic and fungicidal activity of thiabendazole against the pathogenic strains was evaluated by a tube dilution procedure using Sabouraud's Dextrose medium containing 10 per cent heat-inactivated horse serum. The preparation of the inocula was similar to that described above for the saprophytic fungi. The final fungal suspensions were such that 0.1 nil imparted a slight turbidity to the test medium.
Following inoculation, the tubes were incubated at 37° C and growth was recorded at intervals over a 20-day period. Since the various fungi did not grow at the same rate, the final readings for each culture were made when heavy growth was evident in the non-medicated tubes. The minimal inhibitory concentration in the medicated tubes was considered to be the lowest drug level which prevented growth. The fungicidal effect of the drugs was evaluated by subculturing 0.05 to 0.1 ml from each of a series of drug tubes bracketing the inhibitory concentration in the fungistatic tests. Subcultures were made to Sabouraud Dextrose Agar slants. The foregoing inocula contained visible mycelium or yeast-like sediment. The presence or absence of growth was recorded after 8 to 21 days incubation at 37° C.
RESULTS

Fungistatic activity against saprophytic fungi:
The results of in vitro experiments on the fungistatic activity of thiabendazole against a series of saprophytic fungi are presented in Table 1 . Thiabendazole was found to be a potent antimycotic agent ag&nst a number of the genera Fungistatic and fungicidal activity of thiabendazole and nystatin (Mycostatin) against pathogenic fungi: Since the results of the fungistatic and fungicidal tests were essentially identical, in the interest of conserving space only the results of the fungicidal tests are presented in (Table 2) .
Thiabendazole was particularly active against the dermatophytes, microsporum and trichophyton and against the strain of Hormodendrum pedrosoi. Fungistatic and fungicidal activity against these microorganisms was observed with concentrations in the range of from 0.5 to 6 ig per ml. Thiabendazole was somewhat superior to nystatin. The strains of Cryptococcus neoformans were also killed by thiabendazole, although rather high concentrations were required to destroy this organism. Moderately high concentrations of thiabeiidazole were required to demonstrate fungistatic and fungicidal activity against Nocardia bra8iliensis, Rhodotorula rubra and Sporotrichum schenckii. At the maximum concentrations tested, thiabendazole was inactive against eight strains of candida.
Fungistatic and fungicidal activity of thiabendazole against griseofulvin-sensitive dermatophytes: Since thiabendazole was effective against dermatophytes, its activity was evaluated in comparison to that of griseofulvin against a number of strains of trichophyton and microsporum.
Here again, the results of the fungistatic and fungicidal tests were essentially identical and therefore in the interest of space only the results of the fungicidal tests are presented in Table 3 . Thiabendazole was found to be highly active against these dermatophytes, and in most instances, it was more active than griseofi.ilvin. 
DISCtJSSION
It is apparent from the data obtained in this study that thiabendazole is a potent, rather broad spectrum, antimycotic agent in vitro.
Microgram amounts of the compound inhibit the growth of a vañety of saprophytic and pathogenic fungi. The compound appears to be highly effective against saprophytic organisms including cultures which produce mycotoxins. It is also highly active against the pathogenic dermatophytes and particularly against the genera microsporum and trichophyton. Equally important are the observations that thiabendazole is fungicidal as well as fungistatic. It is noteworthy that serum has no apparent effect on the efficacy of the compound. These findings suggest, among other things, that thiabendazole may prove to be a useful topical agent for the treatment of superficial fungus infections due to the microsporum and tñchophyton. In addition to its high antifungal potency, thiabendazole is a colorless, stable non-irritating compound which can be applied to mucous membranes in high concentrations. In view of these properties, thiabendazole may also prove of interest in the topical treatment of ocular infections due to fungi. It is obvious from the data reported here and from other reports describing its low toxicity (6) that thiabendazole should be investigated in vivo to determine its value as a therapeutic agent for the treatment of several superficial and deep mycotic infections. It is noteworthy that thia-bendazole is higMy active against Trichophyton rubrum an organism which gives rise to fungus infections of the soles and palms and which does not readily respond to griseofulvin. Similarly, thiabendazole has a high order of activity against Hormodertdrum pedrosoi, an organism which resists all forms of current treatment. In considering the potential of thiabendazole as an antifungal agent in vivo, it is important t4 note that thiabendazole is well tolerated by a variety of animal species even when administered daily over a 2-year period. At times, moderate doses of thiabendazole may induce emesis, but this appears to be a central effect and one which can be suppressed by chiorpromazine or related drugs and which may subside if thiabendazole therapy is continued (3, 6) . Some of the drug is rapidly absorbed following oral administration and as noted in the present paper, plasma levels may be obtained which will inhibit the growth of fungi.
On the other hand, thiabendazole is rather rapidly metabolized and is converted to several metabolic products which are not as active against fungi as the parent compound. In view of these findings, it is difficult at this time to predict the potential value of thiabendazole as a systemic agent for the treatment of fungus infections. It is obvious that in order to be effective, the drug must reach the site of the infecting microorganism and remain there for a sufficient length of time to adversely affect the fungi. This will vary with the nature and site of the infection and the specific organism giving rise to the disease. Available data indicate that orally administered thiabendazole is absorbed by human subjects. However, at present we have little information regarding the concentration and distribution of thiabendazole in the skin and other tissues of man. Moreover, essentially nothing is known about the plasma levels or toxicity following parenteral administration in man. Studies are in progress to obtain such information and to determine the action of thiabendazole against fungi not included in the present report.
Finally, the data obtained in this study lead one to believe that thiabendazole may be useful as an antifungal agent to control fungus growth in feeds and other perishable materials. Its broad antimycotic and anthelmintic spectrum, combined with stability, lack of taste and color, and a low order of toxicity are among its many attributes.
SUMMARY
Thiabendazole is a known potent anthelmintic which, in the present report, has been demonstrated to be higMy active in vitro against a variety of saprophytic and pathogenic fungi. It is particularly active against strains of trichophyton and microsporum and it also inhibits the growth of cultures producing mycotoxins. Serum does not affect the antifungal activity of thiabendazole. Moderate amounts of the drug are absorbed following oral administration and serum from dogs treated perorally or intravenously with thiabendazole inhibits the growth of pathogenic fungi in vitro. Thiabendazole is unusually well tolerated by a variety of animal species even when given daily over a 2-year period. The present report suggests that thiabendazole should prove to be a valuable agent to control the growth of fungi.
